FDA announces changes to ritonavir package insert

Revisions were recently made to the product labeling for Norvir (ritonavir) 100mg soft gelatin capsules and Norvir (ritonavir) 80mg/mL oral solution, marketed by Abbott Laboratories.

The changes address a Phase IV commitment to develop appropriate labeling for patients with hepatic insufficiency. Changes were also made to the Drug Interaction tables, including new information on the co-administration of Warfarin.

Other revisions include minor editorial changes such as renumbering of tables and consolidation of information into specific sections.


Links to other websites are current at date of posting but not maintained.